Adamas Pharmaceuticals reported -5636000 in EBIT for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebit Change
Acadia Pharmaceuticals ACAD:US $ -15301000 28.41M
Adamas Pharmaceuticals ADMS:US -5636000 3.52M
Aerie Pharmaceuticals AERI:US $ -32374000 873K
Aptinyx Inc APTX:US $ -21206000 1.34M
Biocryst Pharmaceuticals BCRX:US $ -44584000 15M
Flexion Therapeutics FLXN:US $ -24158000 7.28M
GlaxoSmithKline GSK:LN 2.67B 712M
Glaxosmithkline GSK:US 2.67B 712M
Gw Pharmaceuticals GWPH:US -21027000 1.78M
Intra Cellular Therapies ITCI:US $ -77323830 8.18M
Marinus Pharmaceuticals MRNS:US -19169000 4.32M
Merk MRK:US $ 5352M 3083M
Neurocrine Biosciences NBIX:US $ 44.5M 23.3M
Novartis NOVN:VX 3.48B 77M
Omeros OMER:US $ -18253000 5.76M
Prothena PRTA:US 109.23M 81.28M
Revance Therapeutics RVNC:US $ -72723000 2.39M
Teva Pharmaceutical TEVA:IT 806M 23M
Zogenix ZGNX:US $ -53870000 1.56M